T-Therapeutics
PrivateLast Round
Series A
Extension
Nov 13, 2025
Total Funding Raised
$91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
T-Therapeutics is a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus® discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
T-Therapeutics Comparables
Compare T-Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbCellera Biologics Inc. | 77% | |
| Mestag Therapeutics | 73% | |
| Twist Bioscience Corporation | 70% | |
T-Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 13, 2025 | ||||
| Series A | Nov 15, 2023 |
Key People
Founding team and executive leadership
T-Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Digitalis Ventures | Series A Extension, Series A |
| BGF | Series A Extension |
| F-Prime Capital | Series A |
| Cambridge Enterprise | Series A, Series A Extension |
| Cambridge Innovation Capital | Series A Extension, Series A |
| F-Prime Capital | Series A Extension, Series A |
| Sanofi Ventures | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 13, 2025
$32M raised in Series A Extension round.
- Mar 9, 2025
Theodora Harold named new Chief Executive Officer.
T-Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about T-Therapeutics's valuation, stock price, and market status.